Danaher Corporation has agreed to acquire Masimo Corporation for $180 per share in an all-cash transaction valued at $9.9 billion. The acquisition represents a significant expansion of Danaher's portfolio in medical technology and monitoring solutions, leveraging Masimo's established market position in patient monitoring and non-invasive measurement technologies.
The deal is anticipated to deliver meaningful financial benefits through multiple channels. In the first full year following close, the acquisition is expected to be accretive to earnings per share by $0.15 to $0.20, with projections indicating accretion of approximately $0.70 per share by year five. Danaher has identified annual cost synergies exceeding $175 million, driven by operational efficiencies and integration of complementary business operations.
Financial analysts have characterized the transaction as strategically sound, citing Masimo's strong recurring revenue base and opportunities for margin expansion through Danaher's operational capabilities. The acquisition aligns with Danaher's historical strategy of acquiring established healthcare companies and implementing operational improvements to drive shareholder value.